Tocilizumab is an interleukin-6 (IL-6) receptor antagonist, a monoclonal antibody that blocks the signalling of the inflammatory messenger interleukin-6. Its US label, sold as Actemra, lists rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, CAR T cell-induced cytokine release syndrome and hospitalised COVID-19 as approved uses. It is given either as an intravenous infusion or as a subcutaneous injection, and it carries a boxed warning about the risk of serious infections. ChEMBL records a first approval in 2005, and its ATC code, L04AC07, places it among the interleukin inhibitors in the group of antineoplastic and immunomodulating agents.
Facts
Classification
Approval Status ATC ClassL: Antineoplastic and Immunomodulating Agents 2 Route of Administration Route of Administration First Approved / Isolated Year Connections
Treats
Source ChEMBL, EMBL-EBI: Tocilizumab approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Tocilizumab approved indications (ChEMBL)
Source ChEMBL, EMBL-EBI: Tocilizumab approved indications (ChEMBL)
Sources
1. Tocilizumab (ChEMBL record)
ChEMBL molecule record CHEMBL1237022, first_approval field
"first_approval": 2005
ChEMBL molecule record CHEMBL1237022, max_phase 4.0 means approved
"max_phase": "4.0"
View the Source2. RxNav RxClass, National Library of Medicine: RxClass ATC classes of Tocilizumab
RxNav RxClass, National Library of MedicineRxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code L04AC (main group L)Quote, RxClass ATC class of the drug (levels 1 to 4); ATC class derived from cited code L04AC (main group L)
"classId": "L04AC", "className": "Interleukin inhibitors", "classType": "ATC1-4"
3. DailyMed, National Library of Medicine: Actemra (tocilizumab) label, DailyMed
DailyMed, National Library of MedicineIndications and usage, rheumatoid arthritisQuote, Indications and usage, rheumatoid arthritis
as an intravenous infusion or as a subcutaneous injection
ChEMBL, EMBL-EBI: ChEMBL molecule record CHEMBL1237022 (Tocilizumab)
ChEMBL, EMBL-EBIatc_classifications of the molecule record; ATC class derived from cited code L04AC07 (main group L)Quote, atc_classifications of the molecule record; ATC class derived from cited code L04AC07 (main group L)
"atc_classifications": [ "L04AC07" ], "molecule_chembl_id": "CHEMBL1237022", "pref_name": "TOCILIZUMAB"
ChEMBL, EMBL-EBI: Tocilizumab approved indications (ChEMBL)
ChEMBL, EMBL-EBITreats: Giant cell arteritis, drug_indication record, maximum phase 4, MeSH heading Giant Cell Arteritis
"max_phase_for_ind": "4.0", "mesh_heading": "Giant Cell Arteritis", "molecule_chembl_id": "CHEMBL1237022"
Treats: Severe Acute Respiratory Syndrome, drug_indication record, maximum phase 4, MeSH heading Severe Acute Respiratory Syndrome
"max_phase_for_ind": "4.0", "mesh_heading": "Severe Acute Respiratory Syndrome", "molecule_chembl_id": "CHEMBL1237022"
Treats: COVID-19, drug_indication record, maximum phase 4, MeSH heading COVID-19
"max_phase_for_ind": "4.0", "mesh_heading": "COVID-19", "molecule_chembl_id": "CHEMBL1237022"
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.